<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cambridge Centre for Brain Repair</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8678F00A-3BE6-4337-B718-79038B60DC50"><gtr:id>8678F00A-3BE6-4337-B718-79038B60DC50</gtr:id><gtr:firstName>Roger</gtr:firstName><gtr:surname>Barker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EBF62057-C51F-47BB-9B80-D3AA4A7ACD29"><gtr:id>EBF62057-C51F-47BB-9B80-D3AA4A7ACD29</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>B.</gtr:otherNames><gtr:surname>Dunnett</gtr:surname><gtr:orcidId>0000-0003-1826-1578</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/249E7AFE-8B8A-4B56-858E-20584CD542BF"><gtr:id>249E7AFE-8B8A-4B56-858E-20584CD542BF</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>Schapira</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2F0392D8-917D-40E5-BB8F-8A16CCF206BE"><gtr:id>2F0392D8-917D-40E5-BB8F-8A16CCF206BE</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Lees</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7B26620B-FEB9-4EF6-884F-8670FC59E3D6"><gtr:id>7B26620B-FEB9-4EF6-884F-8670FC59E3D6</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Brooks</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FB1268E6-53F8-4C6D-BBA3-C8D455ED63C4"><gtr:id>FB1268E6-53F8-4C6D-BBA3-C8D455ED63C4</gtr:id><gtr:firstName>Maria Grazia</gtr:firstName><gtr:surname>Spillantini</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0001067"><gtr:id>72820B99-1C59-4E3E-8441-8BC299A6A82B</gtr:id><gtr:title>The origins of Parkinson's disease and its heterogenity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0001067</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-11-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>291771</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD44B31B-5AC7-4F59-89C8-149A789ADFFA"><gtr:id>AD44B31B-5AC7-4F59-89C8-149A789ADFFA</gtr:id><gtr:title>Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.</gtr:title><gtr:parentPublicationTitle>CNS drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d06efa5d9567e3b92f07af72467511d8"><gtr:id>d06efa5d9567e3b92f07af72467511d8</gtr:id><gtr:otherNames>Williams-Gray CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1172-7047</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9867303D-C5F3-4C90-82AC-0B35308F7DD7"><gtr:id>9867303D-C5F3-4C90-82AC-0B35308F7DD7</gtr:id><gtr:title>The future challenges in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5569c761d204c6033a9730736dccfe4c"><gtr:id>5569c761d204c6033a9730736dccfe4c</gtr:id><gtr:otherNames>Barker RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/13AA7F0F-186B-48EA-8FF0-938A584211DD"><gtr:id>13AA7F0F-186B-48EA-8FF0-938A584211DD</gtr:id><gtr:title>The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f122ac66de0abb5d7586784704acb951"><gtr:id>f122ac66de0abb5d7586784704acb951</gtr:id><gtr:otherNames>Foltynie T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/12B8ED74-A8F7-4349-9597-E902CAB9F5B1"><gtr:id>12B8ED74-A8F7-4349-9597-E902CAB9F5B1</gtr:id><gtr:title>Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d06efa5d9567e3b92f07af72467511d8"><gtr:id>d06efa5d9567e3b92f07af72467511d8</gtr:id><gtr:otherNames>Williams-Gray CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7D7C6CD8-93F4-450D-9326-669A866871C2"><gtr:id>7D7C6CD8-93F4-450D-9326-669A866871C2</gtr:id><gtr:title>No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cc23875dbdf591dfec98dd2283598bc3"><gtr:id>cc23875dbdf591dfec98dd2283598bc3</gtr:id><gtr:otherNames>Goris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53664125-90C7-43B2-8ED3-7AF61B108245"><gtr:id>53664125-90C7-43B2-8ED3-7AF61B108245</gtr:id><gtr:title>Saccadic latency distributions in Parkinson's disease and the effects of L-dopa.</gtr:title><gtr:parentPublicationTitle>Experimental brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9cbb9749bf7e50639403044c4e70caa6"><gtr:id>9cbb9749bf7e50639403044c4e70caa6</gtr:id><gtr:otherNames>Michell AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-4819</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D537FA20-D07E-4B67-BDED-A98A7DA70AEC"><gtr:id>D537FA20-D07E-4B67-BDED-A98A7DA70AEC</gtr:id><gtr:title>A genome wide linkage disequilibrium screen in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f122ac66de0abb5d7586784704acb951"><gtr:id>f122ac66de0abb5d7586784704acb951</gtr:id><gtr:otherNames>Foltynie T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C661AEBD-6B9C-4668-B893-327243C48E06"><gtr:id>C661AEBD-6B9C-4668-B893-327243C48E06</gtr:id><gtr:title>Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d06efa5d9567e3b92f07af72467511d8"><gtr:id>d06efa5d9567e3b92f07af72467511d8</gtr:id><gtr:otherNames>Williams-Gray CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1BB88494-35CB-4507-9F87-7B61A6B64305"><gtr:id>1BB88494-35CB-4507-9F87-7B61A6B64305</gtr:id><gtr:title>Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f122ac66de0abb5d7586784704acb951"><gtr:id>f122ac66de0abb5d7586784704acb951</gtr:id><gtr:otherNames>Foltynie T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/22B47963-ACF3-46BC-A4D7-D760BF326927"><gtr:id>22B47963-ACF3-46BC-A4D7-D760BF326927</gtr:id><gtr:title>Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.</gtr:title><gtr:parentPublicationTitle>CNS drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d06efa5d9567e3b92f07af72467511d8"><gtr:id>d06efa5d9567e3b92f07af72467511d8</gtr:id><gtr:otherNames>Williams-Gray CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1172-7047</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6C95AF5A-31A4-4D1B-BDC9-231A5B69C8BC"><gtr:id>6C95AF5A-31A4-4D1B-BDC9-231A5B69C8BC</gtr:id><gtr:title>No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d06efa5d9567e3b92f07af72467511d8"><gtr:id>d06efa5d9567e3b92f07af72467511d8</gtr:id><gtr:otherNames>Williams-Gray CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/77F2F02D-F383-40A1-A333-7E3B651FD26E"><gtr:id>77F2F02D-F383-40A1-A333-7E3B651FD26E</gtr:id><gtr:title>The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f122ac66de0abb5d7586784704acb951"><gtr:id>f122ac66de0abb5d7586784704acb951</gtr:id><gtr:otherNames>Foltynie T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54986D5D-7929-4A39-BD83-FDDEC6418A0F"><gtr:id>54986D5D-7929-4A39-BD83-FDDEC6418A0F</gtr:id><gtr:title>Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/19d066d8e399eeefd6d789616fbf1279"><gtr:id>19d066d8e399eeefd6d789616fbf1279</gtr:id><gtr:otherNames>Lewis SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/64B0FAAD-5F85-42F1-ACE4-797F45477525"><gtr:id>64B0FAAD-5F85-42F1-ACE4-797F45477525</gtr:id><gtr:title>Biomarkers and Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9cbb9749bf7e50639403044c4e70caa6"><gtr:id>9cbb9749bf7e50639403044c4e70caa6</gtr:id><gtr:otherNames>Michell AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0001067</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>